Molecular Partners (MOLN) Q3 2026 earnings review
Molecular Partners cuts nearly half its staff as cash shrinks
Molecular Partners, a Swiss biotech developing targeted cancer drugs, is cutting nearly half its staff as cash runs low. Third-quarter operating spending stayed steady at 12 million Swiss francs, leaving 58 million francs in the bank. Chief executive Patrick Amstutz pivoted the company to focus on radioactive cancer treatments after its lead lung cancer drug cleared its first safety check. Management also lifted the bottom end of its full-year spending plan, which by our math leaves fourth-quarter expenses rising about 6% from a year ago.
| Cash and time deposits | CHF 57.5M CHF 67.9M last quarter |
|---|---|
| Operating expenses (Q3) | CHF 12.1M CHF 12.0M a year ago |
| Planned workforce cut | Up to 44% no more than 55 positions |
| Full-year expense outlook | Tightened CHF 50–55M (was CHF 45–55M) |
⚖️ Verdict: 🔴 Bearish
The story got worse because the board added a formal warning in the financial notes casting doubt on the company's ability to continue operating without new funding. Eliminating up to 55 jobs will not lower costs until the second half of 2027, and cash runs out in late 2027. On the positive side, the lead radiotherapy drug showed no severe side effects in its first patient group and finished recruiting its second dose group.
The question now is whether the drugmaker can sign a cash-paying partnership or must issue new shares before its lead drug proves it shrinks tumors in 2027. If December clinical presentations attract a buyer for its older immune drugs, the company can extend its cash timeline; if not, it faces an equity raise under a going-concern warning. Full-year results in March 2027 will show the severance bill and any financing progress.
🐂 Bull Case
Lead Radiotherapy Drug Clears First Safety Check
MP0712 is the Swiss biotech's main experimental cancer treatment. It uses engineered small proteins called DARPins to carry a radioactive lead isotope directly to lung cancer cells. Molecular Partners develops the drug alongside French nuclear group Orano Med. Chief executive Patrick Amstutz said, "Encouraged by the emerging Phase 1/2a data from MP0712, our DLL3 Radio-DARPin for SCLC, we believe now is the time to focus on targeted radiotherapy."
All patients in the first dose level "passed the safety observation period, with no dose-limiting events observed", the company said. Side effects were mild or moderate and cleared before the next treatment cycle. Eight of nine planned US hospital trial sites are now open, and doctors have finished recruiting patients for the second, higher dose level of 105 megabecquerels.
Passing the first safety hurdle matters because radioactive drugs can damage healthy organs if the protein carrier misses its target. Because patients tolerated the initial dose, doctors could raise the radiation level in the second group to test if the drug shrinks tumors.
What to watch: initial safety data at the North America Conference on Lung Cancer in December 2026, followed by tumor-shrinkage results in 2027. Clean safety in the second dose group would allow doctors to keep raising the dose toward an effective treatment level.
Three New Radiotherapy Programs Advance Together
Beyond its lead lung cancer drug, Molecular Partners wants to prove its engineered proteins can carry different radioactive isotopes to several types of tumors. During the third quarter, the drug developer moved three follow-on radiotherapy candidates forward at the same time.
- MP0730: a newly nominated drug targeting the CD70 protein on kidney cancer cells, scheduled to enter human trials in mid-2027
- MP0714: a lung cancer candidate now treating patients in South Africa under a compassionate-care program using lutetium and actinium isotopes
- MP0726: a drug targeting the mesothelin protein on solid tumors, scheduled for its first human imaging scans in the second half of 2026
In mouse studies presented in October, MP0730 showed "strong and sustained tumor uptake relative to healthy tissues, including kidney, liver and blood", the group said. Keeping radiation out of the kidneys has historically been the hardest challenge for small-protein drugs, so clearing that hurdle in animals supports starting human trials next year.
What to watch: first human imaging scans from MP0726 before the end of 2026. Clear tumor images with low kidney uptake in humans would confirm the animal findings across a second cancer target.
🐻 Bear Case
Board Flags Doubts Over Continuing Operations
As a clinical-stage biotech with no products on the market, the Zurich-based group relies on selling shares and signing partnerships to pay for its drug trials. In its press release, management highlighted that its 57.5 million Swiss francs of cash will fund operations into late 2027.
Inside the financial statements, however, the board issued a formal warning. Note 2 states that "material uncertainties exist on the current ability to raise funds and on the level of cash and cash equivalents that may cast significant doubt on the Group's ability to continue as a going concern". The filing adds that the drugmaker has been "unable to obtain additional funding since the last issuance of shares in October 2024".
This warning cuts against the calm tone of the press release because the cash balance only lasts until late 2027, while the new staff cuts will not lower spending until the second half of 2027. To bridge the gap, management is seeking money "either through a direct issuance of shares or alternative structures".
What to watch: any capital raise or licensing deal announced before the full-year report on March 5, 2027. Raising cash before tumor-shrinkage data arrives in 2027 would dilute existing shareholders before the lead drug proves it works.
Orano Med Cost Reimbursements Dropped by Half
In January 2024, Molecular Partners signed an agreement with Orano Med to split research and clinical development costs evenly on shared radioactive drug candidates, including MP0712. Rather than booking these payments as revenue, the Swiss company records them as a direct reduction to its research and development expenses.
In the third quarter, reimbursements from Orano Med dropped 55% from a year ago to 285 thousand Swiss francs, the filing said. Across the first nine months of 2026, partner payments fell 65% to 710 thousand francs, down from 2.03 million francs in the same period last year.
Even though third-quarter payments picked up from 77 thousand francs in the second quarter as the US trial opened more hospital sites, Orano Med covered only 3.4% of total research spending in the quarter, by our math. That leaves the Swiss biotech paying almost the entire research bill from its own shrinking cash reserves.
What to watch: Note 5.1 in the full-year financial statements in March 2027 for fourth-quarter Orano Med reimbursements. A figure remaining below 500 thousand francs would show that the partnership does little to slow the company's cash drain.
Older Immune Drugs Seek Outside Buyers
Before shifting to radiotherapy, Molecular Partners spent years developing immune cell engagers — engineered proteins designed to wake up a patient's immune system inside a tumor. This group includes MP0533 for blood cancer, MP0317 for bile duct cancer, and MP0632.
As part of its reorganization, the company stopped prioritizing internal spending on these drugs. Instead, it will look to advance them "through strategic partnerships and platform-derived spin-out opportunities", the release said. Investigators will present final dose-escalation data for the blood cancer drug MP0533 at a hematology conference in December 2026.
Putting the entire immune-drug portfolio up for licensing or spin-out means the biotech will not fund their next clinical trials on its own. If outside pharmaceutical companies do not license them after the December presentations, years of research spending on those programs will bring in no cash.
What to watch: any partnership or spin-out deal following the American Society of Hematology meeting in December 2026. Failing to sign a partner by mid-2027 would leave the immune portfolio shelved with no financial return.
👓 Other Themes
Management Plans to Cut Nearly Half the Staff
On October 29, the drugmaker notified Zurich authorities of a plan to "reduce its current workforce by no more than 55 positions, representing a potential of ~44% of all positions". After a second-quarter headcount of 116.7 full-time staff, this follows a June 2025 lay-off that cost 2.7 million francs. Management cannot yet estimate the severance bill, and cost savings will not take full effect until the second half of 2027.
💲 Other KPIs
Cash reserves fell by 10.4 million Swiss francs from the second quarter, down 15.4% in three months. Over the past year, total liquidity dropped from 105.0 million francs in the third quarter of 2025 as the group funded its clinical trials. The company holds no borrowed debt, only 2.7 million francs in lease obligations.
The long-term pension obligation on the balance sheet dropped 66.2% from 8.1 million Swiss francs at the end of 2025. Independent actuaries updated the pension math at the end of September, recording a 2.8 million franc non-cash gain in the third quarter and 6.1 million francs across the first nine months from higher pension plan asset values.
The average number of shares used to calculate loss per share rose 2.5% from 37.40 million a year ago. While the biotech has not sold new shares to investors since October 2024, it vested 1.0 million employee stock awards during the first nine months of 2026, pulling shares out of its treasury reserve.
🔮 Guidance
Raised at the bottom end. Management lifted the lower bound of its full-year spending plan by 5 million Swiss francs, raising the middle of the range to 52.5 million francs, or a 9.6% drop from 2025 by our math. That leaves about 13.4 million francs of spending for the fourth quarter, up 11.2% from the third quarter and up 6.4% from a year ago. Non-cash costs make up 5 million francs.
Unchanged. The Swiss drugmaker still expects its 57.5 million Swiss francs of cash to pay for operations and capital spending into the fourth quarter of 2027. In the first quarter of 2026, management had shortened this timeline from 2028 to late 2027. Keeping the late-2027 date unchanged despite announcing a 44% staff cut shows that severance costs and notice periods will delay any cash savings until the second half of 2027.
❓ Key Questions
How much cash will the 55 staff cuts cost?
Management said it cannot estimate the severance bill until full-year results in March 2027. Because the 2025 layoff of roughly 36 people cost 2.7 million Swiss francs, cutting up to 55 positions could consume several million francs of cash before savings start in mid-2027.
Why does the staff cut not extend the cash runway?
Molecular Partners plans to eliminate up to 44% of its jobs by the second quarter of 2027, yet its cash forecast still runs out in the fourth quarter of 2027. Investors need to know the monthly cash burn rate expected once the cuts finish.
Why did Orano Med reimbursements fall 65% this year?
Orano Med splits development costs evenly on MP0712 and MP0726, and MP0712 is now running an active US hospital trial. Yet partner reimbursements totaled only 710 thousand francs across nine months, down from 2.03 million francs a year ago.
Will the company sell shares before MP0712 efficacy data?
Note 2 flags a going-concern risk and states management is working to raise capital through share sales or other structures. With tumor-shrinkage data not due until 2027, investors need to know if a financing must happen before those results arrive.